Gain of 1q is associated with inferior event-free and overall survival in patients with favorable histology Wilms tumor: A report from the Children's Oncology Group

Eric J. Gratias*, Lawrence J Jennings, James R. Anderson, Jeffrey S. Dome, Paul Grundy, Elizabeth J Perlman

*Corresponding author for this work

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

BACKGROUND Wilms tumor is the most common childhood renal tumor. Although the majority of patients with favorable histology Wilms tumor (FHWT) have good outcomes, some patients still experience disease recurrence and death from disease. The goal of the current study was to determine whether tumor-specific chromosome 1q gain is associated with event-free survival (EFS) and overall survival (OS) in patients with FHWT. METHODS Unilateral FHWT samples were obtained from patients enrolled on National Wilms Tumor Study-4 and Pediatric Oncology Group Wilms Biology Study (POG 9046). 1q gain, 1p loss, and 16q loss were determined using multiplex ligation-dependent probe amplification. RESULTS The 8-year EFS rate was 87% (95% confidence interval [95% CI], 82%-91%) for the entire cohort of 212 patients. Tumors from 58 of 212 patients (27%) displayed 1q gain. A strong relationship between 1q gain and 1p/16q loss was observed. The 8-year EFS rate was 76% (95% CI, 63%-85%) for patients with 1q gain and 93% (95% CI, 87%-96%) for those lacking 1q gain (P =.0024). The 8-year OS rate was 89% (95% CI, 78%-95%) for those with 1q gain and 98% (95% CI, 94%-99%) for those lacking 1q gain (P =.0075). Gain of 1q was not found to correlate with disease stage (P =.16). After stratification for stage of disease, 1q gain was associated with a significantly increased risk of disease recurrence (risk ratio estimate: 2.72; P =.0089). CONCLUSIONS Gain of 1q may provide a valuable prognostic marker with which to stratify therapy for patients with FHWT. A confirmatory study is necessary before this biomarker is incorporated into the risk stratification schema of future therapeutic studies. Cancer 2013;119:3887-3894.

Original languageEnglish (US)
Pages (from-to)3887-3894
Number of pages8
JournalCancer
Volume119
Issue number21
DOIs
StatePublished - Nov 1 2013

Fingerprint

Wilms Tumor
Disease-Free Survival
Histology
Confidence Intervals
Survival Rate
Neoplasms
Recurrence
Multiplex Polymerase Chain Reaction
Chromosomes
Biomarkers
Odds Ratio
Pediatrics
Kidney
Survival
Therapeutics

Keywords

  • Wilms tumor
  • chromosome 1
  • kidney
  • pediatrics
  • prognosis

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

@article{975ce84e4e3d4e99b7adf64970bd87f2,
title = "Gain of 1q is associated with inferior event-free and overall survival in patients with favorable histology Wilms tumor: A report from the Children's Oncology Group",
abstract = "BACKGROUND Wilms tumor is the most common childhood renal tumor. Although the majority of patients with favorable histology Wilms tumor (FHWT) have good outcomes, some patients still experience disease recurrence and death from disease. The goal of the current study was to determine whether tumor-specific chromosome 1q gain is associated with event-free survival (EFS) and overall survival (OS) in patients with FHWT. METHODS Unilateral FHWT samples were obtained from patients enrolled on National Wilms Tumor Study-4 and Pediatric Oncology Group Wilms Biology Study (POG 9046). 1q gain, 1p loss, and 16q loss were determined using multiplex ligation-dependent probe amplification. RESULTS The 8-year EFS rate was 87{\%} (95{\%} confidence interval [95{\%} CI], 82{\%}-91{\%}) for the entire cohort of 212 patients. Tumors from 58 of 212 patients (27{\%}) displayed 1q gain. A strong relationship between 1q gain and 1p/16q loss was observed. The 8-year EFS rate was 76{\%} (95{\%} CI, 63{\%}-85{\%}) for patients with 1q gain and 93{\%} (95{\%} CI, 87{\%}-96{\%}) for those lacking 1q gain (P =.0024). The 8-year OS rate was 89{\%} (95{\%} CI, 78{\%}-95{\%}) for those with 1q gain and 98{\%} (95{\%} CI, 94{\%}-99{\%}) for those lacking 1q gain (P =.0075). Gain of 1q was not found to correlate with disease stage (P =.16). After stratification for stage of disease, 1q gain was associated with a significantly increased risk of disease recurrence (risk ratio estimate: 2.72; P =.0089). CONCLUSIONS Gain of 1q may provide a valuable prognostic marker with which to stratify therapy for patients with FHWT. A confirmatory study is necessary before this biomarker is incorporated into the risk stratification schema of future therapeutic studies. Cancer 2013;119:3887-3894.",
keywords = "Wilms tumor, chromosome 1, kidney, pediatrics, prognosis",
author = "Gratias, {Eric J.} and Jennings, {Lawrence J} and Anderson, {James R.} and Dome, {Jeffrey S.} and Paul Grundy and Perlman, {Elizabeth J}",
year = "2013",
month = "11",
day = "1",
doi = "10.1002/cncr.28239",
language = "English (US)",
volume = "119",
pages = "3887--3894",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "21",

}

Gain of 1q is associated with inferior event-free and overall survival in patients with favorable histology Wilms tumor : A report from the Children's Oncology Group. / Gratias, Eric J.; Jennings, Lawrence J; Anderson, James R.; Dome, Jeffrey S.; Grundy, Paul; Perlman, Elizabeth J.

In: Cancer, Vol. 119, No. 21, 01.11.2013, p. 3887-3894.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Gain of 1q is associated with inferior event-free and overall survival in patients with favorable histology Wilms tumor

T2 - A report from the Children's Oncology Group

AU - Gratias, Eric J.

AU - Jennings, Lawrence J

AU - Anderson, James R.

AU - Dome, Jeffrey S.

AU - Grundy, Paul

AU - Perlman, Elizabeth J

PY - 2013/11/1

Y1 - 2013/11/1

N2 - BACKGROUND Wilms tumor is the most common childhood renal tumor. Although the majority of patients with favorable histology Wilms tumor (FHWT) have good outcomes, some patients still experience disease recurrence and death from disease. The goal of the current study was to determine whether tumor-specific chromosome 1q gain is associated with event-free survival (EFS) and overall survival (OS) in patients with FHWT. METHODS Unilateral FHWT samples were obtained from patients enrolled on National Wilms Tumor Study-4 and Pediatric Oncology Group Wilms Biology Study (POG 9046). 1q gain, 1p loss, and 16q loss were determined using multiplex ligation-dependent probe amplification. RESULTS The 8-year EFS rate was 87% (95% confidence interval [95% CI], 82%-91%) for the entire cohort of 212 patients. Tumors from 58 of 212 patients (27%) displayed 1q gain. A strong relationship between 1q gain and 1p/16q loss was observed. The 8-year EFS rate was 76% (95% CI, 63%-85%) for patients with 1q gain and 93% (95% CI, 87%-96%) for those lacking 1q gain (P =.0024). The 8-year OS rate was 89% (95% CI, 78%-95%) for those with 1q gain and 98% (95% CI, 94%-99%) for those lacking 1q gain (P =.0075). Gain of 1q was not found to correlate with disease stage (P =.16). After stratification for stage of disease, 1q gain was associated with a significantly increased risk of disease recurrence (risk ratio estimate: 2.72; P =.0089). CONCLUSIONS Gain of 1q may provide a valuable prognostic marker with which to stratify therapy for patients with FHWT. A confirmatory study is necessary before this biomarker is incorporated into the risk stratification schema of future therapeutic studies. Cancer 2013;119:3887-3894.

AB - BACKGROUND Wilms tumor is the most common childhood renal tumor. Although the majority of patients with favorable histology Wilms tumor (FHWT) have good outcomes, some patients still experience disease recurrence and death from disease. The goal of the current study was to determine whether tumor-specific chromosome 1q gain is associated with event-free survival (EFS) and overall survival (OS) in patients with FHWT. METHODS Unilateral FHWT samples were obtained from patients enrolled on National Wilms Tumor Study-4 and Pediatric Oncology Group Wilms Biology Study (POG 9046). 1q gain, 1p loss, and 16q loss were determined using multiplex ligation-dependent probe amplification. RESULTS The 8-year EFS rate was 87% (95% confidence interval [95% CI], 82%-91%) for the entire cohort of 212 patients. Tumors from 58 of 212 patients (27%) displayed 1q gain. A strong relationship between 1q gain and 1p/16q loss was observed. The 8-year EFS rate was 76% (95% CI, 63%-85%) for patients with 1q gain and 93% (95% CI, 87%-96%) for those lacking 1q gain (P =.0024). The 8-year OS rate was 89% (95% CI, 78%-95%) for those with 1q gain and 98% (95% CI, 94%-99%) for those lacking 1q gain (P =.0075). Gain of 1q was not found to correlate with disease stage (P =.16). After stratification for stage of disease, 1q gain was associated with a significantly increased risk of disease recurrence (risk ratio estimate: 2.72; P =.0089). CONCLUSIONS Gain of 1q may provide a valuable prognostic marker with which to stratify therapy for patients with FHWT. A confirmatory study is necessary before this biomarker is incorporated into the risk stratification schema of future therapeutic studies. Cancer 2013;119:3887-3894.

KW - Wilms tumor

KW - chromosome 1

KW - kidney

KW - pediatrics

KW - prognosis

UR - http://www.scopus.com/inward/record.url?scp=84886086836&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886086836&partnerID=8YFLogxK

U2 - 10.1002/cncr.28239

DO - 10.1002/cncr.28239

M3 - Article

C2 - 23983061

AN - SCOPUS:84886086836

VL - 119

SP - 3887

EP - 3894

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 21

ER -